Optimization of human keratinocyte culture to develop a tissue bio-engineered human skin model

Guerrero-Calvo, J; Fernández-González, A.; Lizana-Moreno, A.; Montes-Ramos, P; Fernández, N.; Ruiz-Garcia, A.; Espinosa, Olga; Ordóñez-Luque, A.; Sierra-Sánchez, Álvaro; Arias‐Santiago, Salvador

doi:10.1016/j.jcyt.2017.02.340

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biomedicines 2020, 8, x FOR PEER REVIEW 4 of 28 24 h before. The skin substitute is maintained in culture for approximately 1-2 weeks, and after that, it undergoes a pressure dehydration process in which it acquires its final thickness when water is removed [4,22]. This is a successful example within the multitude of procedures described for manufacturing artificial human skin.…”

Section: Applicationsmentioning

confidence: 99%

Bioengineered Skin Intended as In Vitro Model for Pharmacosmetics, Skin Disease Study and Environmental Skin Impact Analysis

et al. 2020

View full text Add to dashboard Cite

This review aims to be an update of Bioengineered Artificial Skin Substitutes (BASS) applications. At the first moment, they were created as an attempt to replace native skin grafts transplantation. Nowadays, these in vitro models have been increasing and widening their application areas, becoming important tools for research. This study is focus on the ability to design in vitro BASS which have been demonstrated to be appropriate to develop new products in the cosmetic and pharmacology industry. Allowing to go deeper into the skin disease research, and to analyze the effects provoked by environmental stressful agents. The importance of BASS to replace animal experimentation is also highlighted. Furthermore, the BASS validation parameters approved by the OECD (Organisation for Economic Co-operation and Development) are also analyzed. This report presents an overview of the skin models applicable to skin research along with their design methods. Finally, the potential and limitations of the currently available BASS to supply the demands for disease modeling and pharmaceutical screening are discussed.

show abstract

Section: Applicationsmentioning

confidence: 99%